The number of patients suffering from sick sinus syndrome will increase from 78,000 in 2012 to 172,000 by 2060, according to the American College of Cardiology. In Asia Pacific, atrioventricular blockage conditions are on the rise, especially among patients of coronary heart diseases. Based on such factors, the global cardiac pacemaker market will rise at a CAGR of 8.7% from 2015 to 2023, says Transparency Market Research (TMR). Currently, more than four million people across the world have a pacemaker or some other cardiac rhythm management device and more than 700,000 new implants happen every year, indicating that the global cardiac pacemaker market is on a growth trajectory, says TMR.
Read Full Report: http://www.transparencymarketresearch.com/cardiac-pacemakers-market.html
Of the many factors, the increasing number of individuals that are above the age of 65 years is a high impact driver of this market. As stated by the U.S. Census Board, currently, individuals over 65 years of age represent 13% of the overall population; this is expected to be 20% by 2030. Similarly, as per the World Health Organization, the number of geriatrics across the world will be 1.5 billion by 2050. Japan and Germany have an increasingly aging population, which will be a significant impact driver for the global cardiac pacemaker market in the foreseeable years.
Leap in Design and Functionality Features of Pacemakers Promotes Demand
Pacemakers have been in use for a very long time and are considered essential for people with arrhythmic heart beats. Although these devices are effective, they have concerns that are primarily associated with these two aspects – first, the surgical procedure involved wherein an incision is made in the upper chest to place the device underneath the skin, and second, the wired connection between the device and the heart muscle that delivers the needed thrust to control the heart beats.
Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=393
The wire is associated with several problems, such as, fracturing of the wire over a period of time or getting absorbed into the healing tissue surrounding the wire, leading to a buildup of scar tissue. Removal of the wire because of either reason is complicated as well. Thus, leadless pacemakers have been sought in recent years. Due to technological advances, the manufacture of leadless devices has become a reality in the near recent times. As a result, the various aspects of the device that include the electronics, generator, and pacing element are minuscule, thus saving a surgical procedure altogether. Instead, a transvascular procedure is used, wherein a puncture in a vein in the leg advances the device all the way to the heart’s right ventricle.
Nanostim, developed by St Jude Medical, is the world’s first commercial and self-contained leadless pacemaker. In 2012, the first successful implants of leadless pacemakers were carried out on a group of 11 patients at Homolka Hospital in Prague, Czech Republic. In December of the same year, the feasibility study of the leadless pacemaker on 33 patients was completed in order to ascertain the pacing and handling of the device over a year. The feasibility study was carried out across three centers in Europe.
Following this, the leadless pacemaker made its way into the U.S. with the first patient receiving the device in the Mount Sinai Hospital in December 2014. This paved the way for a pivotal trial, called as Leadless II carried out by the U.S. FDA, on a total of almost 100 patients in the U.S., Australia, and Canada.
With such advances becoming the norm in the cardiac pacemaker market, growth is expected to remain constant in the foreseeable future.
